NEJM January 22,2026:Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.

This clinical trial investigated whether patients who underwent a successful catheter ablation for atrial fibrillation still require powerful blood thinners to prevent future complications. Researchers compared the effectiveness of rivaroxaban against aspirin over a three-year period by monitoring for strokes and hidden brain injuries using MRI technology. The study ultimately found no significant difference between the two medications in reducing the risk of major embolic events for this specific group of patients. These results suggest that for those whose heart rhythm has been restored, the additional protection offered by stronger anticoagulants may not outweigh the potential risks or provide a meaningful advantage over simpler treatments.